CDA | Evidence Driven
CDA | Evidence Driven

cipaglucosidase alfa and miglustat

Details

Generic Name:
cipaglucosidase alfa and miglustat
Project Status:
Pending
Therapeutic Area:
Pompe disease
Manufacturer:
Amicus Therapeutics Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0871-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​For long-term treatment in adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​For long-term treatment in adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 23, 2024